Differential effects of myosin activators on myocardial contractile function in nonfailing and failing human hearts
The second-generation myosin activator danicamtiv (DN) has shown improved function
compared with the first-generation myosin activator omecamtiv mecarbil (OM) in nonfailing …
compared with the first-generation myosin activator omecamtiv mecarbil (OM) in nonfailing …
Danicamtiv affected isometric force and cross-bridge kinetics similarly in skinned myocardial strips from male and female rats
Myotropes are pharmaceuticals that have recently been developed or are under
investigation for the treatment of heart diseases. Myotropes have had varied success in …
investigation for the treatment of heart diseases. Myotropes have had varied success in …
[PDF][PDF] What frozen human hearts can tell us about treating heart failure
RQ Crawford, H Tigro, C Solís - American Journal of …, 2025 - journals.physiology.org
Heart failure (HF) is still the leading cause of death in the US with nearly 6.7 million 9
Americans 20 years of age or older suffering from it (1). Heart failure can be defined as 10 a …
Americans 20 years of age or older suffering from it (1). Heart failure can be defined as 10 a …
[HTML][HTML] Danicamtiv reduces myosin's working stroke but enhances contraction by activating the thin filament
B Scott, L Greenberg, C Squarci, KS Campbell… - …, 2024 - pmc.ncbi.nlm.nih.gov
Heart failure is a leading cause of death worldwide, and even with current treatments, the 5-
year transplant-free survival rate is only~ 50–70%. As such, there is a need to develop new …
year transplant-free survival rate is only~ 50–70%. As such, there is a need to develop new …